|
Volumn 4, Issue 12 SUPPL. 2, 2000, Pages
|
The cost-effectiveness of screening for latent tuberculosis infection
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ISONIAZID;
ISONIAZID PLUS RIFAMPICIN;
RIFATER;
CHEMOPROPHYLAXIS;
CONFERENCE PAPER;
COST EFFECTIVENESS ANALYSIS;
COST OF ILLNESS;
HIGH RISK POPULATION;
HUMAN;
LIVER TOXICITY;
MEDICAL INFORMATION;
PREVALENCE;
PRIORITY JOURNAL;
TUBERCULIN TEST;
TUBERCULOSIS;
ADOLESCENT;
ADULT;
AGED;
ANTITUBERCULAR AGENTS;
CHILD;
COST-BENEFIT ANALYSIS;
DECISION TREES;
FEMALE;
HUMANS;
MALE;
MARKOV CHAINS;
MASS SCREENING;
MIDDLE AGED;
MODELS, ECONOMETRIC;
QUALITY-ADJUSTED LIFE YEARS;
TUBERCULOSIS;
UNITED STATES;
|
EID: 0034517794
PISSN: 10273719
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
Times cited : (23)
|
References (22)
|